Presentation

Autism spectrum disorders (ASD) affect around 1 % of the population and are characterised by difficulties in social interactions and communication as well as repetitive behaviours. The precise symptoms and their severity vary widely from one person to another; some are only mildly afflicted and can lead relatively independent lives, while others are severely disabled and require a lot of specialist care. People with ASD often have other conditions, including epilepsy, depression, anxiety and attention deficit hyperactivity disorder (ADHD). Today, there are no drugs designed specifically to treat ASD; instead, those affected are treated with medicines designed for other conditions.

By creating the first European clinical trial network for autism, AIMS-2-TRIALS aims to improve and personalize treatments for people with ASD (precision medicine). It will do this by creating a pipeline for the development, testing and implementation of new treatments with stakeholder involvement at every stage. The project will establish a global network of clinical trials to validate biological markers and endpoints and reliably show whether a treatment is effective and appropriate. As part of this project coordinated by King's College, the CEA team will conduct genetic imaging studies.

AIMS-2-TRIAL is a continuation of the EU-AIMS project (2012-2018).

COORDINATOR : King's College London

Joliot Institute Contact: Vincent Frouin (vincent.frouin@cea.fr)

website :

https://www.aims-2-trials.eu/

H2020 agreement id: 777394